SCHEMBL137803

SCHEMBL137803

Nc1ccc(-c2ccoc2C(=O)O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGTR1 P30556 1/20 0.42
AGTR2 P50052 1/20 0.42
TAAR1 Q96RJ0 2/20 0.37
ALPL P05186 1/20 0.37
SLC22A12 Q96S37 2/20 0.36
XDH P47989 1/20 0.36
TDP1 Q9NUW8 4/20 0.36
CYP3A4 P08684 2/20 0.36
TP53 P04637 2/20 0.36
KMT2A Q03164 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HSD17B10 Q99714 1/20 0.35
POLB P06746 2/20 0.34
ESR1 P03372 1/20 0.34
APEX1 P27695 1/20 0.34
MAPK1 P28482 1/20 0.34
ESR2 Q92731 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8138770 0.83 BCL2L1 (0.48) AGTR1AGTR2ALPLSLC22A12XDH
SCHEMBL3983853 0.83 HSD17B10 (0.47) AGTR1AGTR2TDP1TP53KMT2A
SCHEMBL27605316 0.83 KMT2A (0.44) AGTR1AGTR2SLC22A12XDHKMT2A
SCHEMBL1549765 0.82 KMT2A (0.46) AGTR1AGTR2SLC22A12XDHKMT2A
SCHEMBL2030709 0.81 AGTR1 (0.44) AGTR1AGTR2TP53ALDH1A1KDM4E
SCHEMBL2318665 0.81 SMN1; SMN2 (0.42) AGTR1AGTR2TDP1TP53KMT2A
SCHEMBL27605308 0.81 PTPN1 (0.41) AGTR1AGTR2SLC22A12XDHKMT2A
SCHEMBL244322 0.81 GPR35 (0.43) AGTR1AGTR2KMT2AMAPK1KDM4E
SCHEMBL141046 0.81 MAPT (0.37) TAAR1KMT2AALDH1A1MAPK1L3MBTL1
SCHEMBL27605354 0.81 AGTR1 (0.45) AGTR1AGTR2TAAR1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102459215-B 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmacy acceptable salt thereof DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) 2016-03-02 CN disclosed
CN-102459215-B 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmacy acceptable salt thereof DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) 2016-03-02 CN disclosed
US-8883824-B2 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-11 US disclosed
US-8883824-B2 3-(4-aminophenyl)-2-furancarboxylic acid derivative and pharmaceutically acceptable salt thereof SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-11 US disclosed
EP-2431362-A4 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO (JP) 2012-10-10 EP disclosed
CN-102459215-A 3- (4-aminophenyl) -2-furancarboxylic acid derivatives and pharmaceutically acceptable salts thereof DAINIPPON SUMITOMO PHARMA CO 2012-05-16 CN disclosed
CN-102459215-A 3- (4-aminophenyl) -2-furancarboxylic acid derivatives and pharmaceutically acceptable salts thereof DAINIPPON SUMITOMO PHARMA CO 2012-05-16 CN disclosed
EP-2431362-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-03-21 EP disclosed
EP-2431362-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Dainippon Sumitomo Pharma Co., Ltd. (JP) 2012-03-21 EP disclosed
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-03-08 US disclosed
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-03-08 US disclosed
WO-2010131669-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 大日本住友製薬株式会社 (JP) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120059012-A1 3-(4-AMINOPHENYL)-2-FURANCARBOXYLIC ACID DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACSL3, SLCO4C1, SLC38A7 AGTR1 61/4885AGTR2 40/4885TAAR1 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.